DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-367/S-041, S-042, S-049

Genzyme Corporation
Attention: Suzanne M. Sensabaugh, MS
Associate Director, Regulatory Affairs
One Kendall Square
Cambridge, MA 02139-1562 U.S.A.

Dear Ms. Sensabaugh:

Please refer to the following supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cerezyme (imiglucerase for injection):

SLR-041: dated September 28, 1999; received September 29, 1999

This application, submitted as a "Changes Being Effected" supplemental new drug application, provides for the following changes in the 200/400 Unit dose vial package insert:

1) addition of an anaphylactoid reaction statement in the WARNINGS section;
2) addition of a pulmonary hypertension statement in the PRECAUTIONS section;
3) addition of cyanosis to the list of symptoms of hypersensitivity and updating on the rate of occurrence of adverse reactions in the ADVERSE REACTIONS section

SLR-042: dated November 11, 1999; received November 12, 1999; amended January 21, 2000

This application, submitted as a "Changes Being Effected" supplemental new drug application, provides for identical changes noted in SLR-041. However, this revision is only for the 200 Unit Vial dosage package insert.

According to a July 11, 2001, telephone conversation between Ms. Suzanne Sensabaugh, Regulatory Affairs, and Dr. Samuel Wu of this Division, the package insert for the 200 Unit Vial dosage submitted in SLR-042 is no longer being used in the U.S. Therefore, S-042 will be administratively closed.

SLR-049: dated January 8, 2001; received January 9, 2001

This application provides for changes in the DOSAGE AND ADMINISTRATION section of the 200/400 Unit dose vial package insert to include the addition of a statement regarding the potential for protein flocculation following dilution, the use of a low protein binding 0.2 μm in-line filter, and the deletion of the infusion rate.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the labeling submitted in supplement-049 on January 8, 2001.

Please submit the copies of final printed labeling (FPL) electronically to each application according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 20-367/S-041, -042, -043." Approval of these submissions by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Samuel Y. Wu, Pharm.D., Regulatory Project Manager, at 301-827-6431.

Sincerely,

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research